ARKG is trading at $47.50 (-3.94%) amid profit-taking after substantial recent gains.

  • It gained 10.46% on August 19 and 3.80% on August 21.
  • Its concentrated high-growth biotechnology holdings are sensitive to risk appetite, Treasury yields, and headline-driven flows. The broader market is modestly lower, with the S&P 500 down 0.26% and Nasdaq Composite down 0.55%.
  • No clear healthcare-wide negative catalyst is evident; positive Moderna-Merck cancer data primarily benefited those companies rather than ARKG’s largest holdings.